Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the
end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir
when administered with standard, medium and high dose rifampicin.
Phase:
Phase 4
Details
Lead Sponsor:
Helen Reynolds
Collaborators:
Desmond Tutu HIV Centre Infectious Disease Institute, Kampala, Uganda